EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First‐Line Treatment of HER2 + MBC : A Multicenter Real‐World Study

Meiqiong Kuang iD, Jianbin Li iD, Li Bian, Shaohua Zhang, Tao Wang, Zhongsheng Tong, Quchang Ouyang, Zefei Jiang

Cancer Medicine · 2026

DOI: 10.1002/cam4.71932 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Meiqiong Kuang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Trastuzumab, Antibodies, Monoclonal, Humanized, Taxoids, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The National Science and Technology Major Project of China, The National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Taxanes combined with trastuzumab plus either pertuzumab (THP) or pyrotinib (THPy) are standard first‐line treatments for HER2‐positive metastatic breast cancer (HER2+ MBC). Nevertheless, direct comparative evidence remains insufficient. This study compared the efficacy and safety of THP vs. THPy for HER2+ MBC.

Methods

The multicenter retrospective study comprised patients treated in first‐line with either THP or THPy from January 2018 to March 2025. Confounding factors were adjusted using 1:1 propensity score matching (PSM) and multivariable Cox regression. Progression‐free survival (PFS) was the primary endpoint, with clinical benefit rate (CBR), objective response rate (ORR), and safety as secondary endpoints.

Results

A total of 411 patients were enrolled (THP: 148; THPy: 263). After matching, 139 pairs formed. Before PSM, patients in the THPy group experienced a longer median PFS than those in the THP group (23.6 vs. 19.3 months, HR = 0.72, 95% CI: 0.53–0.97, p = 0.031). After PSM, THPy still provided a PFS benefit (23.6 vs. 17.3 months, HR = 0.68, 95% CI: 0.48–0.97, p = 0.033), with an adjusted HR of 0.44 (95% CI 0.30–0.66, p < 0.001). Before PSM, the THPy group had a lower ORR than the THP group (69.2% vs. 81.1%, p = 0.009), but after PSM, this disparity in ORR was no longer significant (74.1% vs. 79.9%, p = 0.254), and CBR remained comparable between the two groups throughout. THPy showed potential PFS benefit in the subgroup with de novo stage IV disease and liver metastasis. Gastrointestinal toxicities were more common in the THPy group, with diarrhea being the most prominent (any grade: 76.1%; grade ≥ 3: 22.7%).

Conclusions

THPy may provide PFS benefit over THP in HER2+ MBC, with suggestive advantages in patients with de novo stage IV disease and liver metastasis. A higher frequency of diarrhea and other gastrointestinal toxicities was observed in the THPy regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabAntibodies, Monoclonal, HumanizedTaxoidsAntineoplastic Combined Chemotherapy ProtocolsAminoquinolinesBreast NeoplasmsAcrylamidesHumansFemaleErb-b2 Receptor Tyrosine KinasesRetrospective StudiesMiddle AgedAgedAdultProgression-Free SurvivalTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

HER2‐positivePertuzumabPyrotinibfirst‐line treatmentmetastatic breast cancer

Substanzen

pyrotinibTrastuzumabAntibodies, Monoclonal, HumanizedTaxoidsErb-b2 Receptor Tyrosine KinasesAminoquinolinesAcrylamidespertuzumabERBB2 protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Senior Department of Oncology, Chinese PLA General Hospital, Beijing, China.
  • Department of Breast Medicine, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China.
  • Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, Hunan, China.

ORCID-Profile: Meiqiong Kuang, Jianbin Li

Förderung

  • The National Science and Technology Major Project of China
  • The National Natural Science Foundation of China

Zitieren

APA

Kuang, M., Li, J., Bian, L., Zhang, S., Wang, T., Tong, Z., Ouyang, Q., & Jiang, Z. (2026). Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First‐Line Treatment of HER2 + MBC : A Multicenter Real‐World Study. Cancer Medicine. https://doi.org/10.1002/cam4.71932

Vancouver

Kuang M, Li J, Bian L, Zhang S, Wang T, Tong Z, et al. Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First‐Line Treatment of HER2 + MBC : A Multicenter Real‐World Study. Cancer Medicine. 2026. doi:10.1002/cam4.71932

BibTeX
@article{Kuang2026,
  author = {Kuang, Meiqiong and Li, Jianbin and Bian, Li and Zhang, Shaohua and Wang, Tao and Tong, Zhongsheng and Ouyang, Quchang and Jiang, Zefei},
  title = {Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First‐Line Treatment of HER2 + MBC : A Multicenter Real‐World Study},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71932}
}
Kostenlos starten →